- Home
- AVNS vs MLTX Comparison
AVNS vs MLTX Comparison
Compare AVNS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNS
- MLTX
- Stock Information
- Founded
- AVNS 2014
- MLTX 2021
- Country
- AVNS United States
- MLTX Switzerland
- Employees
- AVNS N/A
- MLTX N/A
- Industry
- AVNS Industrial Specialties
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- AVNS Health Care
- MLTX Health Care
- Exchange
- AVNS Nasdaq
- MLTX Nasdaq
- Market Cap
- AVNS 591.9M
- MLTX 535.3M
- IPO Year
- AVNS N/A
- MLTX N/A
- Fundamental
- Price
- AVNS $11.41
- MLTX $9.10
- Analyst Decision
- AVNS
- MLTX Buy
- Analyst Count
- AVNS 0
- MLTX 9
- Target Price
- AVNS N/A
- MLTX $37.63
- AVG Volume (30 Days)
- AVNS 635.6K
- MLTX 10.0M
- Earning Date
- AVNS 10-29-2025
- MLTX 11-06-2025
- Dividend Yield
- AVNS N/A
- MLTX N/A
- EPS Growth
- AVNS N/A
- MLTX N/A
- EPS
- AVNS N/A
- MLTX N/A
- Revenue
- AVNS $692,500,000.00
- MLTX N/A
- Revenue This Year
- AVNS $0.25
- MLTX N/A
- Revenue Next Year
- AVNS $1.33
- MLTX N/A
- P/E Ratio
- AVNS N/A
- MLTX N/A
- Revenue Growth
- AVNS 1.48
- MLTX N/A
- 52 Week Low
- AVNS $9.30
- MLTX $5.95
- 52 Week High
- AVNS $23.68
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- AVNS 43.33
- MLTX 23.15
- Support Level
- AVNS $11.31
- MLTX $8.18
- Resistance Level
- AVNS $12.00
- MLTX $9.54
- Average True Range (ATR)
- AVNS 0.42
- MLTX 2.00
- MACD
- AVNS -0.07
- MLTX -3.65
- Stochastic Oscillator
- AVNS 12.82
- MLTX 5.47
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.